CSBR - Champions Oncology, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
12.77
-0.08 (-0.62%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close12.85
Open12.94
Bid12.77 x 1100
Ask13.54 x 800
Day's Range12.70 - 13.45
52 Week Range3.05 - 17.90
Volume205,072
Avg. Volume253,315
Market Cap142.569M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateDec 5, 2018 - Dec 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.33
Trade prices are not sourced from all markets
  • Has Champions Oncology (CSBR) Outpaced Other Medical Stocks This Year?
    Zacks9 days ago

    Has Champions Oncology (CSBR) Outpaced Other Medical Stocks This Year?

    Is (CSBR) Outperforming Other Medical Stocks This Year?

  • Bull Of The Day: Champions Oncology (CSBR)
    Zacks17 days ago

    Bull Of The Day: Champions Oncology (CSBR)

    Bull Of The Day: Champions Oncology (CSBR)

  • Best ETFs & Stocks From the Top Sector of Q3
    Zacks20 days ago

    Best ETFs & Stocks From the Top Sector of Q3

    Healthcare was the best-performing sector of the third quarter, jumping 14.1% - its highest quarterly gain since the first quarter of 2013.

  • Zacks23 days ago

    Tech Breaks S&P Out of Slump

    Tech Breaks S&P Out of Slump

  • Looking for a Top Momentum Pick? Why Champions Oncology (CSBR) is a Great Choice
    Zackslast month

    Looking for a Top Momentum Pick? Why Champions Oncology (CSBR) is a Great Choice

    Does Champions Oncology (CSBR) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Zackslast month

    S&P, Dow Nearing All-Time Highs

    S&P, Dow Nearing All-Time Highs

  • PR Newswirelast month

    Champions Oncology Reports Record Quarterly Revenue of $6.2 Million

    Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019 HACKENSACK, N.J. , Sept. 13, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range ...

  • PR Newswirelast month

    Champions Oncology to Participate at the Janney Montgomery Scott Healthcare Conference 2018 in New York

    HACKENSACK, N.J., Sept. 13, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced that management will participate at the Janney Montgomery Scott Healthcare Conference 2018 on Monday, September 17th in New York. To schedule a meeting, please contact your conference representative or James Carbonara at Hayden IR. Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.

  • Champions Oncology (CSBR) Q1 Earnings Preview: How Are Events Shaping Up?
    Zackslast month

    Champions Oncology (CSBR) Q1 Earnings Preview: How Are Events Shaping Up?

    Champions Oncology (CSBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • PR Newswire2 months ago

    Champions Oncology to Announce First Quarter Financial Results on Thursday, September 13, 2018

    HACKENSACK, N.J., Aug. 28, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2018, on Thursday, September 13, 2018, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EDT (1:30 p.m. PDT). A replay of the call will be available by dialing 877-481-4010 or 919-882-2331 and entering Passcode: 37415, or by accessing the Investor tab of the company's website within 72 hours.

  • PR Newswire2 months ago

    Champions Oncology Granted Full Accreditation by the AAALAC

     The new facility was designed and constructed in the first half of 2017 with operations initiated in July 2017. The purpose-built facility has state-of-the-art equipment, technology, and infrastructure, including individually ventilated caging, and automated water systems. Dr. Ronnie Morris, CEO of Champions Oncology commented: "The rapidity with which our Program attained Full Accreditation by AAALAC highlights our dedication to animal welfare and providing the highest quality research data to our collaborators. AAALAC International is a private, nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Nearly 1,000 companies, universities, hospitals, government agencies and other research institutions in 46 countries have earned AAALAC accreditation, demonstrating their commitment to responsible animal care and use.

  • PR Newswire3 months ago

    Champions Oncology Reports Record Annual Revenue Exceeding $20M for Fiscal Year Ended April 30, 2018

    Expects Revenue Growth of at Least 20% for Fiscal Year 2019 HACKENSACK, N.J. , July 26, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions ...

  • PR Newswire3 months ago

    Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 26, 2018

    HACKENSACK, N.J., July 12, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter ended April 30, 2018, on Thursday, July 26, 2018, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EDT (1:30 p.m. PDT). A replay of the call will be available by dialing 877-481-4010 or 919-882-2331 and entering Passcode: 34360, or by accessing the Investor tab of the company's website within 72 hours.

  • PR Newswire4 months ago

    Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies

    HACKENSACK, N.J., June 18, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that they have partnered with NSABP Foundation, Inc. (formerly National Surgical Adjuvant Breast and Bowel Project) and Puma Biotechnology, Inc. (PBYI) to develop patient derived xenograft (PDX) models in two multi-center co-clinical PDX trials. The first trial, NSABP FB10 is a phase II study evaluating the combination of trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer (NCT02236000) and is currently enrolling patients.

  • PR Newswire6 months ago

    Champions Oncology to Present at the 3rd annual Disruptive Growth & Healthcare Conference on May 9th

    HACKENSACK, N.J., May 3, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at the 3rd annual Disruptive Growth & Healthcare Conference on Wednesday, May 9th at 8:40am. The conference is being hosted by RHK Capital and ReedSmith LLP, at Reed Smith's offices located at 599 Lexington Avenue. The 2018 Disruptive Growth & Healthcare Conference will offer the exclusive opportunity to discover life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models.

  • PR Newswire6 months ago

    Champions Oncology Adds Amy Wesa, Ph.D, as Director of Immuno-Oncology Research

    HACKENSACK, N.J., May 1, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that Amy Wesa, Ph.D, has joined the company as Director of Immuno-Oncology Research. Ronnie Morris, CEO of Champions Oncology commented, "The appointment of Dr. Wesa demonstrates our long-term commitment to help pharmaceutical companies make better decisions as they develop immunotherapeutics. Immuno-oncology represents a fast growing part of the oncology drug pipeline.

  • PR Newswire7 months ago

    Champions Oncology to Present at The MicroCap Conference on April 10th in New York City at the Essex House

    HACKENSACK, N.J., April 4, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at this year's MicroCap Conference on Tuesday, April 10, 2018 at 9:30am. The MicroCap Conference will take place in New York City at the Essex House on April 9th and 10th.

  • ACCESSWIRE7 months ago

    Blog Exposure - Lexicon Announced NDA and MAA Submissions for Sotagliflozin to Treat Adults with Type-1 Diabetes

    Stock Monitor: Champions Oncology Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 28, 2018 / Active-Investors.com has just released a free research report on Lexicon Pharmaceuticals, Inc. (NASDAQ: ...

  • PR Newswire7 months ago

    Champions Oncology Reports Quarterly Revenue of $5.1 Million

    Company Generates Positive Cash Flow from Operations; Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2018 HACKENSACK, N.J. , March 15, 2018 /PRNewswire/ -- Champions Oncology, ...

  • ACCESSWIRE7 months ago

    Champions Oncology, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Champions Oncology, Inc. (NASDAQ: CSBR ) will be discussing their earnings results in their Q3 Earnings Call to be held on March 15, 2018, at 4:30 PM Eastern ...

  • Does Champions Oncology Inc’s (NASDAQ:CSBR) Past Performance Indicate A Stronger Future?
    Simply Wall St.7 months ago

    Does Champions Oncology Inc’s (NASDAQ:CSBR) Past Performance Indicate A Stronger Future?

    Assessing Champions Oncology Inc’s (NASDAQ:CSBR) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple sense check toRead More...

  • PR Newswire7 months ago

    Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 15, 2018

    HACKENSACK, N.J., March 7, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2018, on Thursday, March 15, 2018, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EST (1:30 p.m. PST). A replay of the call will be available by dialing 877-481-4010 or 919-882-2331 and entering Passcode: 26851, or by accessing the Investor tab of the company's website within 72 hours.

  • How Financially Strong Is Champions Oncology Inc (NASDAQ:CSBR)?
    Simply Wall St.8 months ago

    How Financially Strong Is Champions Oncology Inc (NASDAQ:CSBR)?

    Investors are always looking for growth in small-cap stocks like Champions Oncology Inc (NASDAQ:CSBR), with a market cap of US$39.12M. However, an important fact which most ignore is: how financiallyRead More...

  • PR Newswire8 months ago

    Champions Oncology to Participate at the 30th Annual ROTH Conference

    HACKENSACK, N.J., Feb. 26, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will participate at the 30th Annual Roth Conference and will conduct one-on-one meetings. The conference will be held March 11-13, 2018 at The Ritz Carlton, Laguna Niguel in Orange County, CA and is by invitation only. Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.

  • PR Newswire8 months ago

    Motivated Patients with ROS1 Cancer Initiate Global Research Study

    SAN CARLOS, Calif. and HACKENSACK, N.J., Feb. 21, 2018 /PRNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology (CSBR) and the ROS1ders announce the commencement of a global study to gain a deeper understanding of ROS1-positive cancer. The study is developing patient-derived xenografts (PDX) models for ROS1-fusion driven cancers to understand what drives tumor development, therapeutic response and acquired resistance to enable the development of new and more effective therapies against this under-studied molecular subset of cancer.